A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
Might be worth tuning in for: https://twitter.com/CellPressNews/status/1286096187754459142?s=20 @Robert Garry, we need to discuss challenge trials at some point :wink:.
-
Wow - that Cell discussion with Gao and Shi should be fun...Not sure I can bring you over to the "dark side" and Ithink it is possible someone could die, but - yeah IMO - controlled trials better than "wild" trials given the circumstances.
-
Yeah, should be interesting. George popped up on a NASEM meeting last week and it was pretty interesting to get his take. A little different than here in the US... I say we just make the whole of Florida a challenge trial :wink:
-
2020-07-23 08:14
Andrew Rambaut
I am talking to Wellcome Vaccines dept tomorrow about challenge trials. They are considering which stocks to manufacture. I am not that sure what to tell them other than a basal D614G.
-
Yeah, NIAID asked us about getting an isolate from a "mild infection"... Well, mild, severe, moderate, chances are they're all the same. I agree on getting something as basal on the tree as possible (that's assuming D614G _does not_ show resistance to neutralization - which is a real concern (e.g., GP A82V in Ebola does that).
-
Jeremy's preprint suggests it is sensitive to ABs
-
But I guess the point is it is the dominant form and will remain so.
-
The UK has been playing hard and loose with viruses in the past, so I wouldn't be surprised if we'd see challenge trials from them. IMO, this virus is much too dangerous with too many uncertain long-term effects to deliberately infect people - especially given the HUGE number of cases we have in this country.